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Abstract
Introduction Mammary tumors in mice are categorized by using
morphologic and architectural criteria. Immunolabeling for
terminal differentiation markers was compared among a variety
of mouse mammary neoplasms because expression of terminal
differentiation markers, and especially of keratins, provides
important information on the origin of neoplastic cells and their
degree of differentiation.
Methods Expression patterns for terminal differentiation
markers were used to characterize tumor types and to study
tumor progression in transgenic mouse models of mammary
neoplasia (mice overexpressing Neu  (Erbb2),  Hras,  Myc,
Notch4, SV40-TAg, Tgfa, and Wnt1), in spontaneous mammary
carcinomas, and in mammary neoplasms associated with
infection by the mouse mammary tumor virus (MMTV).
Results On the basis of the expression of terminal differentiation
markers, three types of neoplasm were identified: first, simple
carcinomas composed exclusively of cells with a luminal
phenotype are characteristic of neoplasms arising in mice
transgenic for Neu, Hras, Myc, Notch4, and SV40-TAg; second,
'complex carcinomas' displaying luminal and myoepithelial
differentiation are characteristic of type P tumors arising in mice
transgenic for Wnt1, neoplasms arising in mice infected by the
MMTV, and spontaneous adenosquamous carcinomas; and
third, 'carcinomas with epithelial to mesenchymal transition
(EMT)' are a characteristic feature of tumor progression in Hras-,
Myc-, and SV40-TAg-induced mammary neoplasms and PL/J
and SJL/J mouse strains, and display de novo expression of
myoepithelial and mesenchymal cell markers. In sharp contrast,
EMT was not detected in papillary adenocarcinomas arising in
BALB/cJ mice, spontaneous adenoacanthomas, neoplasms
associated with MMTV-infection, or in neoplasms arising in mice
transgenic for Neu and Wnt1.
Conclusions Immunohistochemical profiles of complex
neoplasms are consistent with a stem cell origin, whereas
simple carcinomas might originate from a cell committed to the
luminal lineage. In addition, these results suggest that the
initiating oncogenic events determine the morphologic features
associated with cancer progression because EMT is observed
only in certain types of neoplasm.
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Introduction
Architectural and cytological patterns have been the basis
for mammary tumor categorization for more than a century
[1]. Over the past 20 years, immunohistochemistry has
added a molecular dimension to the categorization of mam-
mary neoplasms: altered expression of oncogenes, onco-
suppressor genes, hormone receptors, and cytoskeletal
proteins have been identified as useful indicators of dis-
ease outcome. Gene microarray analysis has confirmed the
importance of many of these histological prognosticators
[2-4], which – in conjunction with clinical features such as
lymph node status, tumor size, and tumor grade [5] – are
undeniably useful. However, these prognosticators do not
seem to be useful to identify the pathways that lead to tum-
origenesis and cancer progression.
Transgenic mouse models of mammary cancer have added
considerably to our knowledge of human breast
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tumorigenesis. More specifically, in addition to dissecting
the molecular mechanisms underlying mammary develop-
ment and the initial steps of mammary neoplastic transfor-
mation, mouse models have shown that activation of a
particular pathway is reflected in specific histologic pat-
terns [6,7].
In view of the evidence that terminal differentiation markers
are important pathway markers [7] and prognostic predic-
tors [4,8-10], we compared the expression of terminal dif-
ferentiation markers and some morphologic features of
spontaneous and transgene-induced mammary tumors in
mice. This study corroborates molecular [2,3,11-14] and
immunohistochemical [4,7,15] studies in human cancer
patients and mouse models of human cancer recommend-
ing that, in addition to the broadly accepted and well-docu-
mented use of architectural features [6,7,16-19],
diagnostic criteria should also take into account the cell
types into which neoplastic cells differentiate.
We have identified neoplastic cells with luminal, myoepithe-
lial, and mesenchymal phenotypes. Myoepithelial differenti-
ation is 'constitutive' to specific tumor types, for example
adenosquamous carcinomas, adenomyoepitheliomas, and
adenocarcinomas associated with the active mouse mam-
mary tumor virus (MMTV) and the wingless-related MMTV
integration site 1 (Wnt1) transgene. In contrast, in neo-
plasms dependent on the myelocytomatosis oncogene
(Myc), Harvey rat sarcoma viral oncogene 1 (Hras), and
SV40 T antigen (SV40-TAg) transgenes, myoepithelial dif-
ferentiation is an important event in the specific type of
tumor progression characterized by epithelial to mesenchy-
mal transition (EMT). The occurrence in some transgenic
models of distinct proteotypic expression patterns, defined
as groups of neoplasms expressing a specific set of termi-
nal differentiation markers, suggests an as yet unreported
degree of variability in transgenic models, perhaps reflec-
tive of the diversity of second-hit mutations in these tumors.
Finally, specific types of spontaneous mammary tumors are
histologically and immunohistochemically indistinguishable
from some of the transgene-induced mammary tumor mod-
els. This provides the background information to test the
hypothesis that tumor phenotype is a predictor of tumor
genotype.
Methods
Mice
The pathology database [20] of The Jackson Laboratory
was searched from 1987 to 2001 for spontaneous mam-
mary tumors in production and research colonies. Slides
were reviewed and categorized on the basis of standard-
ized criteria [17-19,21-23].
In addition, newborns of the following strains were
obtained from The Jackson Laboratory Induced Mutant
Resource (Bar Harbor, ME): C57BL/6J-
Tg(WapTAg)1Knw, FVB/N-Tg(WapNotch4)10Rnc/J,
B6SJL-Tg(Wnt1)1Hev/J (hereafter abbreviated B6SJL-
Wnt1), FVB/NJ-Tg(Wnt1)1Hev/J (hereafter abbreviated
FVB-Wnt1), FVB/N-Tg(MMTVneu)202Mul/J, FVB/N-
Tg(WapMyc)212Bri/J, FVB/N-Tg(WapHRAS)69Lln YSJL/J,
and FVB/NJ-Tg(MMTVTGFA)254Rjc/J and B6D2-
Tg(MMTVTGFA)254Rjc/J. Mice were weaned at 3 weeks
of age and genotyped by polymerase chain reaction.
Detailed information on the genotyping protocols and
breeding conditions are available online at http://
jaxmice.jax.org/info/index.html. These mice were aged until
they developed mammary masses, which were fixed by
immersion in Fekete's acid–alcohol–formalin. Slides were
sectioned at 5–6 µm and stained with hematoxylin and
eosin (H&E).
Immunohistochemistry
Consecutive sections (5–6 µm thick) on Superfrost Plus
slides (Fisher Scientific, Fair Lawn, NJ) of paraffin-embed-
ded neoplasms were immunolabeled for α-smooth muscle
actin (SMA; Sigma, St Louis, MO), keratin 1 (KRT2-1, here-
after abbreviated K1; BabCo, Richmond, CA), keratin 5
(KRT2-5, hereafter abbreviated K5; BabCo), keratin 6
(KRT2-6, hereafter abbreviated K6; BabCo), keratin 10
(K1-10, hereafter abbreviated K10; Babco), keratin 13
(KRT13, hereafter abbreviated K13; Sigma), keratin 14
(KRT1-14, hereafter abbreviated K14; BabCo), keratin 17
(KRT1-17, hereafter abbreviated K17; PA Coulombe, The
Johns Hopkins University, Baltimore, MD) [24], keratins 8/
18 (KRT8 and KRT18, hereafter abbreviated K8/18; Pro-
gen, Heidelberg, Germany), vimentin (Biomeda, Foster
City, CA), filaggrin (BabCo), involucrin (Babco), loricrin
(Babco), and trichohyalin (T-T Sun, The New York Univer-
sity School of Medicine, New York, NY) as described pre-
viously [25]. All these antibodies were mouse-specific
except the antibodies against K13, trichohyalin, and vimen-
tin, which were raised against human proteins, the antibody
against K8/18, which was raised against bovine keratins,
and the antibody against SMA, which was raised against
avian proteins. The anti-SMA antibody recognizes aortic α2
smooth muscle actin (ACTA2) and enteric γ2 smooth mus-
cle actin [26].
In brief, the method was as follows. Deparaffinized slides
were gradually hydrated. Endogenous peroxidase activity
was quenched by incubation with 3% hydrogen peroxide in
methanol for 20 min at room temperature (20–25°C). Heat-
mediated antigen retrieval in citrate buffer at pH 6.0 was
used for the antibodies targeted at K8/18 and vimentin.
Slides were washed and were incubated for 30 min with
blocking serum (10% normal fetal calf serum diluted in
phosphate-buffered saline). Excess blocking serum was
blotted and the slides were incubated overnight at 4°C with
primary antibodies diluted in phosphate-buffered saline.Available online http://breast-cancer-research.com/content/6/6/R668
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Secondary biotinylated anti-mouse or anti-rabbit antibody
was applied for 30 min at room temperature, followed by
incubation with the avidin-biotin complex (45 min). The
reaction was developed with the substrate diaminobenzi-
dine (Sigma) and the slides were counterstained with
Mayer's hematoxylin. All spontaneous tumors were labeled
for MMTV gp27 Gag, gp36 Env, and gp52 Env [27]. A
mouse was identified as positive for MMTV if immunolabe-
ling for at least one of the markers was detected in the
tumor or nearby tissues.
Images were captured with a DP70 digital camera (Olym-
pus, Melville, NY) on an Olympus BX41 microscope and
color enhanced and balanced for contrast with Photoshop
6.0 (Adobe, San Jose, CA). Additional photomicrographs
of H&E-stained and immunolabeled slides are archived in
the Mouse Tumor Biology Database, where they can be
viewed on-line at http://tumor.informatics.jax.org [28].
Slide interpretation and scoring of immunolabeling 
intensity
Cell types were defined on the basis of a previous study
that evaluated the expression of the same terminal differen-
tiation markers in the developing mammary gland [29].
Expression of K5, K14, K17, and/or SMA was associated
with a direct contact with a basement membrane and the
morphology of a myoepithelial cell defined myoepithelial
cell differentiation. Absence of labeling for any of the mark-
ers, or labeling for K8/18 along with a polygonal morphol-
ogy, defined luminal cells.
Image analysis (Photoshop 6.0; Adobe, San Jose, CA) was
used to evaluate the ratio of spindloid neoplastic cells on
H&E-stained sections on all tumors with EMT. EMT was
considered significant when more than 1% of the neoplasm
was composed of neoplastic cells having a spindloid to
fusiform shape and blending into the stroma. These cells
had an oval to elongated nucleus with less clumped chro-
matin than epithelial neoplastic cells. Their cytoplasm was
more acidophilic than epithelial neoplastic cells.
Squamous differentiation was defined by the presence of
one or more of the following features: the formation of a
large core of cornified material, the formation of keratin
pearls, the cornification of individual cells, or the presence
of trichohyalin granules or keratohyalin granules. Squa-
mous differentiation was confirmed by immunohistochemi-
cal expression of at least one of the following markers in the
areas of squamous differentiation: K1, K6, K10, filaggrin,
trichohyalin, involucrin, or loricrin, none of which is normally
expressed in cycling mammary glands [29].
The intensity of immunolabeling was scored on a scale of 0
to 3 (immunolabeling levels: 0 = none; 1 = weak; 2 = mod-
erate; 3 = intense). The grade for each cell type was the
product of average labeling intensity and the relative per-
centage of cells (0%, 0; up to 1%, 1; 2–5%, 2; 6–25%, 3;
26–50%, 4; more than 50%, 5) labeled at the predominant
intensity. The outcome for each neoplasm was the sum of
the grades for each cell type. If immunolabeling was
detected in less than 10 cells in a tumor, the tumor was
considered to be negative for this marker.
Morphologic criteria
All tumors were evaluated (presence/absence) on H&E-
stained sections for myoepithelial differentiation, EMT,
squamous differentiation, vascular invasion, proteinaceous
or lipid droplets in neoplastic cells, and ductal differentia-
tion (defined as tubular structures lined by a basal layer of
cells with myoepithelial differentiation and a luminal layer of
cuboidal cells). Type P tumors are neoplasms composed of
a branching network of blind ducts lined by an epithelium at
least two cells thick and terminated by structures resem-
bling the terminal end buds of the pubertal mammary gland
[7]. Macrocysts are large cysts lined by an epithelium one
or two cells thick that occasionally forms small glands. Lac-
tation-responsive plaques are discoid masses composed
of contoured and anastomosed mammary acini at the
periphery and ducts at the center.
Results
Histologic tumor types (Table 1)
Tumors were categorized histologically using the recom-
mendations of the Mouse Models of Human Cancers Con-
sortium categorization scheme [17-19] and the specific
nomenclature applying to certain models [22] or tumor
types [21,23] when applicable.
Spontaneous tumors were papillary adenocarcinomas with
papillae lined by a single layer of cells (n = 6; Fig. 1), pap-
illary adenocarcinomas with papillae lined by two layers of
cells (n = 2; Fig. 2), glandular adenocarcinomas with EMT
(n = 4; Fig. 3), microacinar adenocarcinomas in C3H/HeJ
mice (n = 8; Fig. 4), type P tumors in C3H/HeJ mice (n =
3), adenomyoepitheliomas in BALBc/J mice (n = 5; Fig. 5),
and adenosquamous carcinomas (n = 7; Fig. 6).
All Hras-induced (n = 4; Fig. 7) and Neu-induced (n = 10)
tumors as well as some Myc-induced (n = 4; Fig. 8c,8e,8f)
and SV40-TAg-induced tumors (data not shown) had a
solid pattern. Some SV40-TAg-induced (n = 5; Fig. 9a,9b)
and Myc-induced tumors (n = 9; Fig. 8a,8b,8d) as well as
all Notch4-induced tumors (n = 6) had a glandular pattern.
Some Myc-induced (n = 13; Fig. 8), SV40-TAg-induced (n
= 3; Fig. 9), and Hras-induced (n = 3) carcinomas dis-
played areas of EMT. Some SV40-TAg-induced tumors (n
= 4) had a papillary pattern with papillae lined by epithelial
cells that piled up in a disorderly fashion (data not shown).
Preneoplastic lesions of Tgfa-transgenic mice consisted ofBreast Cancer Research    Vol 6 No 6    Mikaelian et al.
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macrocysts (n  = 8; Fig. 10a) and lactation-responsive
plaques (n = 3; Fig. 10b). All Wnt1-induced tumors (n =
13; Fig. 11) exhibited a type P tumor pattern.
All spontaneous type P tumors (n = 9), all microacinar car-
cinomas in C3H/HeJ mice (n = 8), and one of two papillary
carcinomas in one C3H/HeJ mouse showed immunolabe-
ling for MMTV (data not shown). Proteinaceous and/or lipid
secretion was identified in a small number of tumors in most
transgenic models and spontaneous tumor types (Fig.
2a,2b), although it was observed most consistently in mac-
rocysts and in adenosquamous carcinomas (Fig.
6a,6c,6d,6e).
Table 1
Proteotypic Classification of Spontaneous and Transgenic Mammary Neoplasms Based on Terminal Differentiation Markersa.
Type Strain/ Transgeneb Main patternc Myoepithelial
differentiationd
EMT (%)e K1 K5 K6 K8/18 K10 K14 K17 FLG IVL LOR THH SMA VIM
Simple FVB-Myc Glandular 6/9 4/9 (<1%) + + + ++ +
FVB-Notch4 Glandular 0/6 0 + + +
C57BL6/J-Tag Glandular 1/5 0 + + +
BALB/cJ (mostly) Papillary, 1 cell thick 2/6 0 + + ++ ++ ++
C57BL6/J-Tag Papillary 0/4 0 + + +
FVB-Myc Solid 1/4 3/4 (<1%) + + +
FVB-Neu Solid 0/10 0
Complex FVB and B6D2-Tgfa Macrocyst 6/8 0 + + +++ + + +
FVB and B6D2-Tgfa Lactation plaque 3/3 0 ++ + +++ ++ + +
BALB/cJ Adenomyoepithelioma 5/5 0 + +++ ++ ++ +++ ++
BALB/cJ (mostly) Adenoacanthoma 7/7 0 ++ ++ ++ ++ ++ +++ +++ ++ ++ + + +
C3H/HeJ Microacinar 8/8 0 ++ + ++ ++ +
BALB/cJ, C3H/HeJ Papillary, 2 cells thick 2/2 0 ++ ++ + ++ ++ +++
C3H/HeJ Type P tumor 9/9 0 ++ + ++ ++ ++ + +++
FVB-Wnt1 Type P tumor 6/6 0 ++ ++ +++ ++ ++ + + ++
B6SJL-Wnt1 Type P tumor 7/7 0 + + + ++ + ++
EMT C57BL6/J-Tag Glandular with EMT 2/3 3/3 (6%) +++ +++ ++ ++ +
FVB-Myc Glandular with EMT 4/6 6/6 (20%) + + ++ ++ ++ + +
PL/J and SJL/J Glandular with EMT 4/4 4/4 (38%) ++ + +++ ++ ++ + ++ ++
FVB-Hras Solid with EMT 3/4 3/4 (<1%) + ++ + + +
adata are coded, with "+++" representing highest grades; the intensity of immunolabeling was scored 0–3 (immunolabeling levels: 0 = none; 1 = 
weak; 2 = moderate; 3 = intense); the grade for each cell type was the product of average labeling intensity and the relative percentage of cells (0: 
0; ≤ 1%: 1; 2–5%: 2; 6–25%: 3; 26–50%: 4; >50%: 5) labeled at the predominant intensity; outcome for each neoplasm was the sum of the 
grades for each cell type and the data presented are the average for each group; white boxes indicate an average grade <1; "+" indicates an 
average grade ≥ 1 and <5; "++" indicates an average grade ≥ 5 and <10; "+++" indicates an average grade ≥ 10; EMT, epithelial to 
mesenchymal transition; FLG, filaggrin; IVL, involucrin; K1, keratin 1; K5, keratin 5; K6, keratin 6; K8/18, keratins 8 and 18; K10, keratin 10; K17, 
keratin 17; LOR, loricrin; THH, trichohyalin; SMA, α-smooth muscle actin; VIM, vimentin.
bAbsence of information for the transgene indicates that the tumor arose in a non-transgenic mouse.
cBased on the recommendations of the Annapolis meeting [17–19].
dTumors with myoepithelial differentiation/tumors examined; carcinomas with minimal myoepithelial differentiation arising in mice transgenic for 
Myc were categorized as "simple carcinomas" because myoepithelial differentiation was interpreted as evidence of early EMT.
eTumors with EMT/ tumors examined; the data in parenthesis indicate the average percentage of the tumors comprised of neoplastic cells with a 
mesenchymal phenotype.
Figure 1
Papillary adenocarcinoma lined by an epithelium one cell thick in a  BALB/cJ mouse Papillary adenocarcinoma lined by an epithelium one cell thick in a 
BALB/cJ mouse: neoplastic cells lack myoepithelial differentiation. 
Myofibroblasts are present in the stroma of the neoplasm. Scale bar, 80 
µm.Available online http://breast-cancer-research.com/content/6/6/R668
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Terminal differentiation proteins expression patterns
The neoplasms were categorized into three groups: those
with a pure luminal phenotype (simple carcinomas), those
that constitutively expressed myoepithelial and luminal
markers, and those that were characterized by EMT.
Hampe and Misdorp [30] defined the term complex as 'any
type of neoplasm or proliferation composed of cells resem-
bling both secretory epithelial and myoepithelial cells'. We
therefore used the term 'constitutively complex carcinomas'
to indicate the tumors in which luminal and myoepithelial
cells were arranged as they would be in a normal mammary
gland, suggesting that these two types of cells originated
from the same progenitor cell. The tumors that expressed
myoepithelial markers in the areas of EMT only are desig-
nated 'acquired complex carcinomas' to indicate that
myoepithelial differentiation was absent in the areas repre-
senting the original phenotype of the neoplasms, before the
occurrence of EMT.
Tumor categorization was then redesigned to take into
account not only the architecture of the neoplastic process
[17-19] but also myoepithelial differentiation and EMT,
which were not always apparent on H&E-stained sections.
Keratins 5, 14, and 17, which are generally considered to
be markers of myoepithelial cells [4], were occasionally
identified in suprabasal cells in a variety of neoplasms (Figs
6f,6h,6i,8c,8e,8f,11a).  α-Smooth muscle actin, another
marker of myoepithelial cells, was expressed by suprabasal
cells only in MMTV-associated and Wnt1-induced type P
tumors (Fig. 12c), a feature previously noted by Li and col-
leagues [13].
Neoplasms with a pure luminal phenotype (simple carcino-
mas) were identified in all transgenic models of mammary
carcinogenesis (Fig. 7, Table 1) with the notable exception
of Wnt1-induced carcinomas that had a constitutively com-
plex phenotype. Most (six of nine) glandular carcinomas
arising in mice transgenic for Myc showed a few areas of
myoepithelial differentiation that were interpreted as early
EMT rather than the neoplasms arising from a progenitor
cell common to the luminal and myoepithelial phenotypes;
hence these neoplasms with minimal myoepithelial
Figure 2
Papillary adenocarcinoma lined by an epithelium two cells thick Papillary adenocarcinoma lined by an epithelium two cells thick: there is myoepithelial differentiation of the basal layer (a), whereas suprabasal cells 
have a luminal phenotype (b). Scale bar, 80 µm.
Figure 3
Epithelial to mesenchymal transition (EMT) in a spontaneous neoplasm Epithelial to mesenchymal transition (EMT) in a spontaneous neoplasm: 
neoplastic cells with a spindloid phenotype are labeled strongly for 
vimentin in a glandular carcinoma with EMT in an SJL/J mouse. Scale 
bar, 80 µm.
Figure 4
Microacinar carcinoma in a C3H/HeJ mouse infected by the mouse  mammary tumor virus Microacinar carcinoma in a C3H/HeJ mouse infected by the mouse 
mammary tumor virus. Microacinar carcinomas are characterized by a 
microacinar pattern with prominent myoepithelial differentiation. Scale 
bar, 80 µm.Breast Cancer Research    Vol 6 No 6    Mikaelian et al.
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Figure 5
Adenomyoepithelioma in a BALB/cJ mouse Adenomyoepithelioma in a BALB/cJ mouse: individual cells (a, arrowhead), clusters of cells (a, arrow), and occasionally large areas (b) are not 
labeled by antibodies against terminal differentiation markers of myoepithelial (a) and luminal cells (b) of the mammary gland. Scale bar, 80 µm.
Figure 6
Adenosquamous carcinoma in a BALB/cJ mouse Adenosquamous carcinoma in a BALB/cJ mouse: squamous differentiation is commonly associated with the presence of keratohyalin (a, arrowhead) 
or trichohyalin (b, arrowhead) granules. Squamous differentiation is 'complete', with expression of markers of all layers of the epidermis (c-e). Individ-
ual cells and small clusters of cells fail to express, or express only weakly, any terminal differentiation marker (f-i, arrowheads), whereas myoepithelial 
differentiation is observed in the areas of squamous differentiation (f, i, arrows). Scale bars, 50 µm (a, b) and 80 µm (c-i).Available online http://breast-cancer-research.com/content/6/6/R668
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differentiation were categorized as 'simple' carcinomas.
The only spontaneous neoplasms composed exclusively of
cells with a luminal phenotype were four of six papillary car-
cinomas that, on H&E sections, were characterized by
papillae lined by an epithelium one cell thick.
Constitutively complex carcinomas consisted of spontane-
ous papillary carcinomas lined by an epithelium two cells
thick (Fig. 2), microacinar adenocarcinomas arising in
MMTV-infected C3H/HeJ mice (Fig. 4), type P tumors of
MMTV-infected C3H/HeJ mice (Fig. 12) and Wnt1-trans-
genic mice (Fig. 11), adenomyoepitheliomas (Fig. 5), ade-
nosquamous carcinomas (Fig. 6), and lactation-responsive
plaques and most (six of eight) macrocysts of Tgfa-trans-
genic mice (Fig. 10). Neoplastic cells with a myoepithelial
phenotype were abundant and formed an almost
continuous layer surrounding cells with a luminal pheno-
type in microacinar carcinomas (Fig. 4) and in spontaneous
papillary carcinomas lined by an epithelium two cells thick
(Fig. 2a). In type P tumors, myoepithelial differentiation was
most prominent in the areas of ductal metaplasia and was
minimal or absent in the frond-like areas of the neoplasms
(Fig. 12a). In adenosquamous carcinomas, myoepithelial
differentiation was most prominent in the areas of squa-
mous differentiation (Fig. 6f,6i), and was often absent in the
glandular areas.
In adenomyoepitheliomas (n  = 5), large proportions of
suprabasal cells were labeled for K5, K6, K8/18, K14, and
K17, with K1 being expressed in only two tumors, and with
duct formation and cornification being identified in four and
three neoplasms, respectively. The morphology of neoplas-
tic cells in adenomyoepitheliomas varied, ranging from fusi-
form to cuboidal. The proteotypic pattern of these cells is
not characteristic of any specific cell type, and these cells
were categorized as 'cells with myoepithelial differentiation'
when in contact with a basement membrane and as 'luminal
cells' when not in contact with a basement membrane.
Neoplastic cells in adenomyoepitheliomas were difficult to
differentiate from stromal myofibroblasts and, as reported
earlier [31], they were negative for SMA.
In lactation-responsive plaques of Tgfa-transgenic mice,
myoepithelial differentiation was most prominent in the
areas of ductal differentiation located at the center of these
lesions (Fig. 10b). The peripheral portions of lactation-
responsive plaques, which morphologically resemble
mammary acini, generally lacked myoepithelial differentia-
tion. Macrocysts were predominantly composed of cells
with a luminal phenotype (Table 1) that occasionally rested
directly on the basement membrane. Segmental portions of
six of eight macrocysts had myoepithelial cells (Fig. 10a).
Immunohistochemistry indicated that the descriptive term
'papillary carcinoma' encompasses a variety of neoplasms.
First, most (four of six) spontaneous papillary carcinomas of
BALB/cJ mice (Fig. 1) and all (four of four) papillary carci-
nomas with a pseudostratified epithelium in SV40-TAg-
transgenic mice were exclusively composed of cells with a
luminal phenotype (simple carcinomas). Cells with myoepi-
thelial differentiation, identified in two of six spontaneous
papillary carcinomas of BALB/cJ mice, were scarce and
might represent entrapped remnants of the normal
mammary gland, because they were located at the periph-
ery of the neoplasm. In spontaneous papillary adenocarci-
nomas characterized by two layers of cells lining neoplastic
papillae, the basal layer was continuous and had a
myoepithelial phenotype (Fig. 2a), whereas cells of the
luminal layer expressed K8/18 (Fig. 2b).
Type P tumors, adenomyoepitheliomas, and adenosqua-
mous carcinomas were characterized by the presence of
subpopulations of cells with a high mitotic index that did not
express terminal differentiation markers, or expressed them
only weakly. In type P tumors, these cells were grouped at
the ends of the fronds, the morphology and
immunohistochemistry of which mimicked terminal end
buds of the pubertal mammary gland [29].
Adenomyoepitheliomas (Fig. 5a,5b) and adenosquamous
carcinomas (Fig. 6f,6g,6h,6i) were populated by individual
cells and clusters of cells with a large open-faced nucleus
and a moderate amount of pale cytoplasm with the appear-
ance of ground glass. These cells were haphazardly distrib-
uted in the solid areas of adenomyoepitheliomas and in the
viable epithelium enclosing cornified debris in
adenosquamous carcinomas. Similar populations of neo-
plastic cells with low expression of terminal differentiation
markers were not detected in the other neoplasms.
Figure 7
Solid carcinoma from a mouse transgenic for Hras Solid carcinoma from a mouse transgenic for Hras: expression of α-
smooth muscle actin in carcinomas is restricted to stromal myofibrob-
lasts and vascular smooth muscle fibers. A similar observation was 
made for carcinomas arising in mice transgenic for Neu (Erbb2) and 
Notch 4 and in most mice transgenic for SV40-TAg (not shown). Scale 
bar, 320 µm.Breast Cancer Research    Vol 6 No 6    Mikaelian et al.
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Carcinomas in B6SJL-Wnt1-and FBV-Wnt1-transgenic
mice were essentially similar and had the classical appear-
ance of a type P tumor. However, they differed slightly with
regard to their proteotypic patterns: squamous
differentiation and expression of K5 and K8/18 was higher
in B6SJL-Wnt1-than in FBV-Wnt1-transgenic mice (Table
1; Fig. 11a,11b).
Tumor progression
EMT, an important morphologic marker of tumor progres-
sion [32,33], was detected in 23 tumors. It was most com-
monly observed in Myc-induced carcinomas although it
was also identified in Hras-and in SV40-TAg-induced car-
cinomas, and in carcinomas spontaneously arising in SJL/J
and PL/J mice. Various proportions of neoplastic cells with
a mesenchymal phenotype expressed vimentin (Figs 3, 8b),
K5 (Fig. 8c), K14 (Fig. 8e), and K17 (Figs 8f, 9b). These
cells consistently expressed SMA but could not be differ-
entiated from myofibroblasts on the basis of the expression
of this antigen alone (Fig. 8a). EMT was also associated
with increased expression of K8/18 (Figs 8d, 9a). In most
cases (20 of 23), a small number of cells with a myoepithe-
lial phenotype were present in the glandular or solid areas
in the immediate vicinity of the areas of EMT (Fig. 8c,8f).
Figure 8
Epithelial to mesenchymal transition (EMT) in a mouse transgenic for Myc Epithelial to mesenchymal transition (EMT) in a mouse transgenic for Myc: EMT is associated with expression of terminal differentiation markers of 
mesenchymal (a,b), myoepithelial (c,e,f) and luminal (d) cells, with de novo acquisition of a myoepithelial phenotype (c,e,f, arrows) by neoplastic 
cells. Scale bars, 80 µm (a-d) and 160 µm (e, f). 'De novo' acquisition of the myoepithelial phenotype is defined as neoplastic cells displaying a 
myoepithelial phenotype in a portion of the neoplasm limited to the vicinity of the areas of EMT, whereas myoepithelial differentiation was lacking in 
the rest of the neoplasm (not shown).
Figure 9
Epithelial to mesenchymal transition (EMT) in a mouse transgenic for SV40-TAg Epithelial to mesenchymal transition (EMT) in a mouse transgenic for SV40-TAg: EMT is associated with increased expression of luminal (a) and 
myoepithelial (b) terminal differentiation markers. Scale bars, 80 µm (a) and 160 µm (b).Available online http://breast-cancer-research.com/content/6/6/R668
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Morphologic progression was also observed in microacinar
adenocarcinomas associated with MMTV infection in C3H/
HeJ mice, where it was characterized by focal to multifocal
acquisition of a solid pattern. Acquisition of the solid pat-
tern was associated with a loss of immunolabeling for
MMTV proteins (data not shown) by neoplastic cells, but
the expression of terminal differentiation markers remained
unaltered.
Neu-induced carcinomas did not display a morphologic
alteration suggestive of tumor progression, although the
tumors evaluated included both metastatic and non-meta-
static neoplasms (data not shown). The markers tested in
this study did not segregate the three cell types classically
described in Neu-and Hras-induced tumors [7]. EMT was
not observed in Notch4-induced carcinomas, although the
glandular pattern of these neoplasms is reminiscent of
Myc-and SV40-TAg-induced carcinomas.
Pathway pathology
Three histologic features of mammary tumors have recently
been related to the activation of specific pathways: myoep-
ithelial differentiation has been associated with activation of
the Wnt pathway [7], squamous metaplasia has been
attributed to β-catenin stabilization [34-37], and alveolar
differentiation and milk secretion are dependent on signal
transducer and activator of transcription 5a [38]. As
expected, all Wnt1-induced carcinomas and spontaneous
type P tumors displayed myoepithelial differentiation. In
addition, myoepithelial differentiation, as assessed by rou-
tine H&E histology or immunohistochemistry, was identified
in spontaneous papillary carcinomas with a bi-stratified epi-
thelium, MMTV-associated microacinar carcinomas, aden-
omyoepitheliomas, and adenosquamous carcinomas.
Squamous metaplasia associated with expression of the
full array of terminal differentiation markers of the supraba-
sal layers of the epidermis was found only in adenosqua-
mous carcinomas (Fig. 6a,6b,6c,6d,6e,6f,6g,6h,6i).
However, squamous metaplasia was also identified in
some MMTV-associated (7 of 9) and Wnt1-induced (12 of
13) type P tumors, Myc-induced carcinomas (7 of 19), ade-
nomyoepitheliomas (3 of 5), and spontaneous carcinomas
exhibiting EMT (1 of 4). In spite of areas histologically con-
sistent with squamous differentiation, MMTV-associated
and transgene-induced type P tumors express only a lim-
ited set of suprabasal markers of the epidermis (Table 1).
For example, K1 and K10, two markers of the stratum
Figure 10
Neoplasms from Tgfa-transgenic mice: myoepithelial differentiation is present in macrocysts (a, arrows) and in lactation-responsive plaques (b,  arrows) Neoplasms from Tgfa-transgenic mice: myoepithelial differentiation is present in macrocysts (a, arrows<) and in lactation-responsive plaques (b, 
arrows). Scale bars, 80 µm (a) and 160 µm (b).
Figure 11
Influence of the background strain on protein expression in type P tumors Influence of the background strain on protein expression in type P tumors: the expression of K5 (a,b) and K8/18 (not shown) is higher, and squa-
mous differentiation (not shown) is more prominent in B6SJL-Wnt1 than in FVB/NJ-Wnt1 mice. Scale bar, 80 µm.Breast Cancer Research    Vol 6 No 6    Mikaelian et al.
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spinosum, were seldom expressed (4 of 30 and 6 of 30
carcinomas, respectively) in neoplasms other than adenos-
quamous carcinomas that exhibited cornification, whereas
involucrin, a marker of the stratum corneum, was expressed
in 19 of 30 such neoplasms.
Discussion
In the present study, interpretation of immunohistochemis-
try results determined the following: first, that expression of
terminal differentiation markers categorizes spontaneous
and transgenic models of mammary neoplasia into 'simple'
carcinomas, 'complex' carcinomas, and carcinomas with
EMT; second, that most neoplasms are composed of mul-
tiple cell populations; and third, that some transgenic and
spontaneous neoplasms are histologically and immunohis-
tochemically indistinguishable, and they provide an oppor-
tunity to test the hypothesis that tumor phenotype predicts
tumor genotype [6,7].
Proteotypic patterns: luminal, luminal/myoepithelial, 
and luminal with EMT
Like human breast tumors [14], most mouse mammary
tumors are exclusively composed of neoplastic cells with a
luminal phenotype, suggesting that they developed from a
progenitor cell committed to the luminal lineage. Progres-
sion to EMT through a myoepithelial stage was observed in
Myc-, Hras-, and SV40-TAg-induced carcinomas, a subset
of spontaneous mammary carcinomas in PL/J and SJL/J
mice, and has also been reported in mice transgenic for
Tgfa [39] and matrix metalloproteinase 3 [40]. Three major
pathways have been implicated in EMT: the pathway con-
trolled by the activation of Hras and Src, the transforming
growth factor β pathway, and the Wnt pathway [32].
Evaluation of the expression of target genes of each of
these pathways is needed to determine the molecular
mechanisms associated with EMT in mouse models of
mammary carcinogenesis.
Type P tumors and microacinar carcinomas constitutively
express myoepithelial markers, whereas expression of
these markers is an indicator of progression in Myc-, Hras-
, and SV40-TAg-induced carcinomas, as it is in some types
of human breast cancer [4,15,41]. As a consequence, mis-
interpretations are likely to occur if tumors are evaluated for
EMT with whole-tumor methodologies such as gene or pro-
tein array technologies.
The genetic background of transgenic mouse models of
mammary tumors might account for differences in the
penetrance, latency, and phenotype of mammary proliferat-
ing lesions [42-44]. The histological phenotype of tumors
arising in Wnt1-transgenic mice was similar, regardless of
the background. However, the background strain influ-
enced the proteotypic pattern of these tumors. This obser-
vation emphasizes the importance of the background strain
in genetically engineered mice, suggests the presence of
tumor modifier genes, and indicates possible similar differ-
ences in humans.
Cell populations
The presence of cells negative or weakly positive for termi-
nal differentiation markers establishes the presence of
compartments of less differentiated cells in specific types
of mammary carcinomas. This observation supports the
hypothesis that undifferentiated cells, so-called 'mammary
stem' cells, are the source of mammary tumors [45,46]. The
histologic phenotype and the proteotypic pattern of type P
tumors constitutes the most striking evidence for this
hypothesis: the fronds in these carcinomas caricatured ter-
minal end buds of the pubertal mammary gland, one of the
compartments in which mammary stem cells are found
[47,48]. Gene array data also support a stem cell origin for
neoplasms arising in mice transgenic for Wnt1 [13]. In ade-
nomyoepitheliomas and adenosquamous carcinomas, the
location of cells that did not express terminal differentiation
markers is suggestive of a ductal origin for these neo-
Figure 12
Type P tumors arise in mice infected by the mouse mammary tumor virus Type P tumors arise in mice infected by the mouse mammary tumor virus. Myoepithelial differentiation is prominent in ductal areas (a, arrowheads), 
whereas suprabasal cells have a luminal phenotype and label for K8/18 (b). Clusters and individual suprabasal cells are labeled by antibodies 
against α-smooth muscle actin (c) and in cells with myoepithelial differentiation (arrowheads). Scale bars, 320 µm (a), 160 µm (b) and 80 µm (c).Available online http://breast-cancer-research.com/content/6/6/R668
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plasms. Interestingly, a second compartment of mammary
stem cells is located in ductal suprabasal cells [49].
In addition to viable cells, a large proportion of neoplasms
contained areas of cornification and necrosis. This
heterogeneous group of non-viable cells has recently been
named 'non-tumorigenic cancer cells' [50]. These cells
need to be differentiated from neoplastic cells with self-
renewal potential, including those cells with invasive or
metastatic potential. Because the populations of 'non-tum-
origenic cancer cells' might account for a significant pro-
portion of some neoplasms, they might interfere with
studies aiming at evaluating RNA or protein expression or
genetic damage at the whole-tumor level.
Pathway pathology
Cardiff and colleagues [6] initially proposed that tumor
architecture and terminal differentiation markers can pre-
dict tumor genotype. The concept has subsequently been
refined [7] and is supported by molecular data [12,13,51].
The present study confirmed that simple carcinomas with a
solid pattern are typical of tumors driven by the Neu and
Ras pathways, whereas type P tumors are a feature of neo-
plasms arising in mice transgenic for Wnt1. That type P
tumors are also found in MMTV-infected mice was
expected because Wnt1 is activated in 75% of mammary
carcinomas arising in C3H/HeJ mice [52], and this obser-
vation supports the validity of the pathway pathology
hypothesis.
Although promising, the pathology pathway concept has
some limitations that are illustrated by our data. For exam-
ple,  Myc-induced carcinomas express large amounts of
whey acidic protein and casein β [53], which should corre-
late with histologic evidence of proteinaceous secretion.
However, only 5 of 20 Myc-induced carcinomas examined
in this study had evidence of proteinaceous or lipid secre-
tion. In addition, the pathology pathway concept predicts
that  Myc-,  Hras-, and Neu-induced carcinomas should
share similar pathways, distinct from those of Wnt1-
induced carcinomas. However, Myc-and  Wnt1-induced
neoplasms are independent of cyclin D1, whereas Hras-
and Neu-induced carcinomas are dependent on cyclin D1
[12,54], indicating that tumor phenotype and tumor geno-
type are not consistently matched.
Conclusions
The observations that mammary neoplasms of mice trans-
genic for H-Ras, Myc, Neu, Notch4 and SV40-Tag, and
that papillary carcinomas of BALB/cJ mice are exclusively
composed of cells with a luminal phenotype, are consistent
with the hypothesis that these neoplasms arise from a cell
committed to the luminal lineage. The fact that adenom-
yoepitheliomas, adenoacanthomas, microacinar carcino-
mas, and type P tumors have a complex phenotype is
consistent with a mammary stem cell origin. In addition, it is
apparent that cancer progression in mammary carcinomas
of mice transgenic for H-Ras, Myc, and SV40-Tag is often
associated with EMT. However, EMT does not occur in
mammary tumors of mice transgenic for Tgfa, Neu, Notch4,
and Wnt1, which indicates that the morphologic features
associated with cancer progression are determined by the
initiating oncogenic events.
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